American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“We issued a guideline update on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
For men whose castration-sensitive prostate cancer was previously treated with systemic therapy, the type of that prior treatment will guide the selection of their next therapy for metastatic castration-resistant prostate cancer (mCRPC).
It’s recommended that androgen-deprivation therapy be continued without stopping for patients with mCRPC.
Read full article.”
More posts featuring American Society of Clinical Oncology on OncoDaily.